Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
desloratadine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | desloratadine 20 mg |
| 2 | ACTIVE_COMPARATOR | desloratadine 20 mg |
| Name | Type | Description |
|---|---|---|
| desloratadine | DRUG | singel dose, oral, 20 mg |
Inclusion Criteria: 1. Outpatients with moderate to severe CU for more than 6 weeks. Urticaria symptoms must comprise wheal and itch. 2. Patients must exhibit spontaneous urticaria lesions in the randomization visit. 3. History of beneficial effects of antihistaminic treatment. 4. Age between 18 an...
Desloratadine is used for chronic urticaria, a condition characterized by recurrent hives. It is being studied as a treatment to reduce skin lesions associated with this condition. The drug is currently in Phase 3 clinical development for this indication.
Desloratadine is a small molecule that works as an antihistamine. It targets the histamine H1 receptor, blocking the action of histamine, which is a key mediator in allergic reactions and the development of hives in chronic urticaria.
Desloratadine is being developed by Pulmonx Corporation, a company traded on the stock exchange under the ticker symbol LUNG. The company is conducting clinical trials to evaluate the drug's efficacy in treating chronic urticaria.
Desloratadine is in Phase 3 clinical development for chronic urticaria. It is an investigational drug and has not yet been approved by regulatory authorities. A Phase 3 trial has been completed to assess its effects on skin lesions in patients with this condition.
Desloratadine has one completed Phase 3 clinical trial registered under NCT00598611. This trial, titled 'Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)', enrolled 29 participants in Germany and was randomized, double-blind, and active-controlled.
Desloratadine is a specific antihistamine drug. It is not the same as other antihistamines, as it has its own unique chemical structure and pharmacological profile. It is being studied specifically for its effects on chronic urticaria, distinguishing it from other treatments in the same class.